Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Published in Business Wire on January 3, 2023
Gilead Sciences and EVOQ Therapeutics announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis and lupus. Congratulations to MCIDT affiliate Dr. James Moon for his involvement in the collaboration!